| 紀錄類型: |
書目-電子資源
: Monograph/item
|
| 正題名/作者: |
Privileged scaffolds in drug discovery/ edited by Bin Yu, Ning Li, Caiyun Fu. |
| 其他作者: |
Yu, Bin. |
| 出版者: |
London, England :Academic Press, Elsevier, : c2023., |
| 面頁冊數: |
1 online resource (xxvi, 961 pages) |
| 內容註: |
Front Cover -- Privileged Scaffolds in Drug Discovery -- Privileged Scaffolds in Drug Discovery -- Copyright -- Contents -- List of contributors -- Preface -- Introduction -- 1 - Thiazole, a privileged scaffold in drug discovery -- 1. Introduction -- 2. Thiazole derivatives as therapeutic agents -- 2.1 Second-generation cephalosporin antibiotics containing thiazole moiety -- 2.2 Third-generation cephalosporin antibiotics containing thiazole substituent -- 2.3 Aminothiazole-containing third-generation cephalosporins for veterinary use -- 2.4 Cephalosporin antibiotics with aminothiazole group used in prodrug forms -- 2.5 Fourth-generation cephalosporin antibiotics containing thiazole nucleus -- 2.6 Fifth-generation cephalosporin antibiotics and monobactams containing aminothiazole group -- 2.7 Thiazole-containing natural products as antimicrobial agents -- 2.8 Antifungal and antiprotozoal agents containing thiazole nucleus -- 2.9 Thiazole derivatives as antifungal and antituberculosis agents -- 2.10 Thiazole derivatives as anticancer drugs -- 2.11 Thiazole-containing antiproliferative agents -- 2.12 Thiazole-containing drugs to treat inflammatory and blood-borne diseases -- 2.13 Thiazole derivative to treat urologic and neurologic disorders -- 2.14 Miscellaneous drugs and useful compounds containing thiazole nucleus -- 2.15 Thiazole-containing essential bioactive compounds -- 3. Conclusions -- Acknowledgments -- References -- 2 - Chalcones: Diverse biological activities and structure-activity relationships -- 1. Background -- 2. Biological activities of chalcone derivatives -- 2.1 Anticancer activity -- 2.1.1 Chalcone-azole hybrids -- 2.1.2 Chalcone-furan/thiophene hybrids -- 2.1.3 Chalcone-indole hybrids -- 2.1.4 Chalcone-pyridine hybrids -- 2.2 Antiinflammatory and antioxidant activities -- 2.2.1 Simple chalcone compounds -- 2.2.2 Licochalcone B. |
| 內容註: |
2.2.3 Licochalcones A and C -- 2.3 Neurodegenerative diseases -- 2.3.1 Trihydroxylated chalcone -- 2.3.2 Imidazole-containing chalcones -- 2.3.3 Halogen-substituted chalcone -- 2.3.4 Chalcone derivatives with di-O-alkylamine substituents -- 2.3.5 Flurbiprofen-chalcone hybrids -- 2.4 Antimalarial activity -- 2.4.1 Chloroquine-containing chalcone analogs -- 2.4.2 Chloroquine-triazole-chalcone hybrids -- 2.4.3 Acetylanine-chalcone hybrids -- 2.5 Antibacterial activity -- 2.5.1 Cationic chalcone derivatives -- 2.5.2 Fluorinated chalcone-triazole hybrids -- 2.5.3 Indole-chalcones -- 2.5.4 Xanthoangelol B derivative -- 2.6 Antiviral activity -- 2.6.1 Alkyl chalcone -- 2.6.2 Licochalcone A -- 2.7 Antidiabetic activity -- 3. Conclusion -- 3.1 Financial and competing interests disclosure -- References -- 3 - Privileged chalcone scaffolds in drug discovery -- 1. Introduction -- 2. Simple chalcones classified by representative mechanisms of action -- 2.1 Michael acceptor-related targeting simple chalcones -- 2.1.1 Targeting IκB kinases -- 2.1.2 Targeting thioredoxin reductase -- 2.1.3 Targeting Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2-antioxidant response element pathway -- 2.2 Other targeting simple chalcones -- 2.2.1 Targeting microtubule formation -- 2.2.2 Targeting ATP-binding cassette G2 -- 2.2.3 Targeting RTKs (receptor tyrosine kinase) -- 2.2.4 Targeting aldose reductase -- 2.2.5 Targeting cyclooxygenase -- 3. Representative hybrid chalcones -- 3.1 Fused hybrids -- 3.1.1 Coumarin-chalcones -- 3.1.2 Indole-chalcones -- 3.1.3 Chalcone-quinoxaline hybrids -- 3.1.4 Other fused hybrid chalcones -- 3.2 Hybrids using linkages -- 3.2.1 Using an amide as a linker -- 3.2.2 Using a diol as a linker -- 3.2.3 Using an ester or ether as a linker -- 3.2.4 Using 1,2,3-triazole as a linker -- 3.2.5 Other linkers. |
| 內容註: |
4. Conclusions and perspectives -- Acknowledgments -- References -- 4 - The N-sulfonyl carboxamide moiety as a privileged structure in approved drugsa -- 1. Introduction -- 2. Physicochemical properties and conformations of N-sulfonyl carboxamides -- 3. Structures and protein targets of marketed drugs 1-27 comprising N-sulfonyl carboxamide moieties -- 4. Perspective -- 5. Conclusion -- Acknowledgments -- References -- 5 - Scaffolds in cytotoxic drugs and novel antitumor molecules interacting with nucleic acids -- 1. DNA intercalators -- 1.1 Ellipticine and its derivatives -- 1.2 Echinomycin and actinomycin -- 2. Topoisomerase inhibitors -- 2.1 Topoisomerase 1 poisons from natural products and their derivatives -- 2.1.1 Camptothecin and its derivatives -- 2.1.2 Nitidine, indenoisoquinoline, lamellarin, and aromathecins -- 2.1.3 Evodiamine and indolocarbazoles -- 2.1.4 Thaspine, kakuol, and pinostrobin -- 2.2 Topoisomerase 1 catalytic inhibitors from natural products and their derivatives -- 2.2.1 β-Lapachone -- 2.2.2 Berberine -- 2.2.3 Sulfoquinovosyl diacylglyceride -- 2.2.4 Globulusal A and flavonoids -- 2.3 Marine natural products as topoisomerase 1 inhibitors -- 2.4 Topoisomerase 2 inhibitors from natural products -- 2.4.1 Podophyllotoxin and its analogs -- 2.4.2 Anthracycline antibiotics and analogs -- 3. G-quadruplex ligands -- 3.1 Telomestatin -- 3.2 Cryptolepine -- 3.3 Schizocommunin -- 3.4 Isaindigotone -- 3.5 Berberine and its analogs -- 3.6 Other natural scaffolds of G4 ligands -- References -- 6 - Triazoles: a privileged scaffold in drug design and novel drug discovery -- 1. Introduction -- 2. 1,2,3-Triazole as bioisosteres -- 2.1 1,2,3-Triazole as amide group bioisosteres -- 2.2 1,2,3-Triazole as heterocycle bioisosteres -- 2.3 1,2,3-Triazole as ester group bioisosteres -- 2.4 1,2,3-Triazole as carboxyl group bioisosteres. |
| 內容註: |
2.5 1,2,3-Triazole as bioisostere for other groups -- 3. Biological significance -- 3.1 Anticancer activity -- 3.2 Antimicrobial activity -- 3.3 Other activities -- 4. Conclusions and prospects -- Acknowledgments -- References -- 7 - Oxazolidinone scaffolds in drug discovery and development -- 1. Introduction -- 2. Launched oxazolidinone antibacterial drugs -- 2.1 Linezolid -- 2.2 Tedizolid -- 3. Modification of linezolid-based oxazolidinone medications -- 3.1 Morpholine ring/C-5 position modifications -- 3.1.1 Morpholine ring modification -- 3.1.2 C-5 modification -- 3.2 Concurrent alterations to C-5 site and morpholine ring -- 3.2.1 Oxazolidinone-biphenyl chalcone hybrid derivative compounds -- 3.2.2 Derivatives of spiropyrimidinetrione oxazolidinone -- 3.2.3 [1,2,5]Triazepane or [1,2,5]oxadiazepane oxazolidinone compounds -- 3.2.4 C-Ring heteroaromatic antibacterial oxazolidinones -- 3.2.5 N-Substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinone derivatives -- 3.2.6 Replaced ligustrazine C-ring oxazolidinone antibiotics -- 3.2.7 Silicon-containing oxazolidinone antibiotics -- 3.2.8 Antibiotic oxazolidinones containing dihydropyridone C-ring unit -- 3.3 Derivatives of tricyclic fused oxazolidinones -- 3.3.1 (Pyridin-3-yl)benzo[1,4]oxazinyl-oxazolidinones -- 3.3.2 (Tetrahydropyridine-4-yl)benzo[1,4]oxazinyl-oxazolidinones -- 3.3.3 Thiomorpholine benzo[1,4]oxazinyl-oxazolidinones -- 3.3.4 Benzo[1,3]oxazinyl-oxazolidinones -- 4. Other novel oxazolidinone derivatives -- 4.1 Azetidinone moieties -- 4.2 Motifs of amide, sulfonamide, and thiourea -- 4.3 Chloroquinoline moieties -- 4.4 Thiazole hybrid moieties -- 4.5 Oxazolidinone derivative-based UDP-3-O-acyl-N-acetylglucosamine deacetylase inhibitor -- 4.6 3-Amino-2-oxazolidinone derivatives -- 5. Effects of oxazolidinone derivatives on other diseases -- 6. Summary and perspective -- References. |
| 內容註: |
8 - Indole and indoline scaffolds in drug discovery -- 1. Background of indole and indoline -- 2. Chemical profile of indole and indoline -- 3. Pharmacologic profile of indole and indoline -- 3.1 Antitumor agents -- 3.1.1 Natural derivatives -- 3.1.2 Kinase inhibitors -- 3.1.3 Histone deacetylase inhibitors -- 3.1.4 Multitargeting agents -- 3.2 Antimicrobial agents -- 3.2.1 Natural antimicrobial agents -- 3.2.2 Synthetic antimicrobial agents -- 3.3 Antiviral agents -- 3.3.1 Anti-human immunodeficiency virus agents -- 3.3.2 Anti-herpes simplex virus agents -- 3.3.3 Anti-hepatitis C virus agents -- 3.3.4 Other antiviral agents -- 3.4 Antiinflammatory agents -- 3.5 Drugs for neurologic disease -- 3.6 Drugs for chronic disease -- 3.7 Other therapeutic applications -- 4. Conclusion and future perspectives -- References -- 9 - Cyanopyridine as a privileged scaffold in drug discovery -- 1. Introduction -- 2. Synthesis of cyanopyridine derivatives -- 2.1 Application of cyanopyridines in anticancer drugs -- 2.1.1 SRC/ABL dual inhibitor -- 2.2 Epidermal growth factor receptor inhibitor -- 2.3 Epidermal growth factor receptor/human epidermal growth factor receptor-2 dual inhibitor -- 2.4 Checkpoint kinase 1 inhibitor -- 2.5 FER inhibitor -- 2.6 PIM-1 inhibitor -- 2.7 Farnesyltransferase inhibitor -- 2.8 B-cell lymphoma 6 inhibitor -- 2.9 Androgen receptor antagonist -- 2.10 DNA methyltransferase 1 inhibitor -- 2.11 Survivin dimerization modulator -- 2.12 Isocitrate dehydrogenase 1 inhibitor -- 2.13 Rearranged during transfection (RET) inhibitor -- 2.14 JAK2 inhibitor -- 2.15 CDK2 inhibitor -- 2.16 General control nonrepressed protein 5 inhibitor -- 2.17 Application of cyanopyridines in antiinflammatory areas -- 2.17.1 IκB kinase β inhibitor -- 2.18 Mitogen-activated protein kinase-activated protein kinase 2 inhibitor -- 2.19 Cyclooxygenase-2 inhibitor. |
| 內容註: |
2.20 Phosphodiesterase-4 inhibitor. |
| 標題: |
Drug development. - |
| 電子資源: |
https://www.sciencedirect.com/science/book/9780443186110 |
| ISBN: |
9780443186127 |